AstraZeneca sued the federal government over drug price reforms on Aug. 25 in Delaware District Court. The complaint, filed by McCarter & English and Hogan Lovells, challenges the drug pricing provisions of the Inflation Reduction Act of 2022. The complaint contends that the provisions conflict with the market-based incentives of the Orphan Drug Act and the Administrative Procedure Act. The case is 1:23-cv-00931, Astrazeneca Pharmaceuticals LP v. Becerra.

This suit was surfaced by Law.com Radar, a source for high-speed legal news and litigation updates personalized to your practice. Law.com Radar publishes daily updates on just-filed federal cases like this one. Click here to get started and be first to know about new suits in your region, practice area or client sector.